Log In
BCIQ
Print this Print this
 

MLN1117, TAK-117 (formerly INK1117)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionInhibitor of Phosphoinositide 3-kinase (PI3K) alpha
Molecular Target Phosphoinositide 3-kinase (PI3K) alpha
Mechanism of ActionPhosphoinositide 3-kinase (PI3K) alpha inhibitor
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$239.0M

$119.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/20/2011

$239.0M

$119.0M

$120.0M

Get a free BioCentury trial today